Exscientia Plc

unmute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press the star key followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. At this time, I would like to introduce Chin Okeka, Associate Director of Strategy and Investor Relations. Chin, you may begin.

Thank you, operator.

Thank you, operator, and welcome everyone to Accenture's full year 2023 financial results and business update conference call. A press release and 20F were issued this morning with our full year 2023 financial results and business update. These documents can be found on our website at investors.accenture.ai, along with the presentation for today's webcast. Before we begin, I'd like to remind you that we may make forward-looking statements on our call. These may include statements about our projected growth, revenue, business models, preclinical and clinical results, and business performance. Actual results may differ materially from those indicated by these statements. Unless required by law, Accenture does not undertake any obligation to update these statements regarding the future or to confirm these statements in relation to actual results. On today's call, I'm joined by Dr. Dave Hallett, Interim Chief Executive Officer and Chief Scientific Officer, and Ben Taylor, Chief Financial Officer and Chief Strategy Officer. Dr. Mike Crams, Chief Medical Officer, will also be available for the Q&A session. And with that, I will now turn the call over to Dave.